Biotech firm Propanc lands $100m for digital asset strategy
Propanc Biopharma, a Nasdaq-listed biotech firm, has secured up to $100 million to bolster its digital asset strategy. Summary Nasdaq-listed…
Propanc Biopharma, a Nasdaq-listed biotech firm, has secured up to $100 million to bolster its digital asset strategy. Summary Nasdaq-listed…